GE HealthCare Technologies Acquires Nihon Medi-Physics to Enhance Precision Care and Imaging

GE HealthCare Expands Precision Care with Acquisition of Nihon Medi-Physics

In a significant strategic move, GE HealthCare announces its plan to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP) by purchasing the remaining 50% stake from Sumitomo Chemical. This acquisition, anticipated to finalize in early 2025 pending regulatory approvals, allows GE HealthCare to enhance its capabilities in radiopharmaceuticals, crucial for SPECT and PET molecular imaging used in disease diagnosis. The integration of NMP’s expertise aligns with GE HealthCare's emphasis on precision medicine, facilitating advanced diagnostic techniques that can lead to timely and effective treatment options for patients.

NMP, a key player in the radiopharmaceutical sector since its establishment in 1973, boasts a diverse product lineup that includes VIZAMYL® Injection for Alzheimer’s detection, DaTSCAN® Injection for evaluating Parkinson’s Disease, and MYOVIEW® for assessing coronary artery disease. With revenues nearing 28.2 billion JPY (approximately $183 million) in 2023 and 13 manufacturing facilities, NMP emphasizes robust research and development in radiotracers and theranostics. This acquisition not only strengthens GE HealthCare's market position but also broadens its portfolio in the rapidly evolving molecular imaging landscape, particularly in Japan, recognized as a significant market for these technologies.

Kevin O’Neill, President & CEO of GE HealthCare's Pharmaceutical Diagnostics segment, underscores Japan's potential as a leader in the $7 billion global molecular imaging market. By acquiring complete control of NMP, GE HealthCare is set to enhance its precision care strategy in Asia. The collaboration promises to drive innovation in molecular imaging and improve patient access to essential diagnostic tools. Sumitomo Chemical's Executive Vice President, Hiroshi Ueda, expresses confidence in GE HealthCare’s leadership, acknowledging the company’s commitment to advancing molecular imaging for patients in Japan and beyond.

In addition to enhancing its product offerings, this acquisition reinforces GE HealthCare’s existing operations in Japan. The company has established a strong foundation with its medical devices and contrast media, which are integral to daily imaging procedures. By consolidating its ownership of NMP, GE HealthCare not only strengthens its operational capabilities but also positions itself to better serve the diagnostic needs of the Japanese healthcare market.

This strategic acquisition represents a pivotal moment for GE HealthCare as it aims to broaden its influence in the global radiopharmaceuticals sector. With a focus on innovation and patient care, GE HealthCare is poised to drive advancements in molecular imaging, ultimately improving diagnostic accuracy and treatment outcomes in the healthcare landscape.